Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.434 | A Randomised Control Trial on the Use of Acupuncture in the Relief of Labour Pain | Prof. Lao Terence |
| 2013.189 | The health effects of traffic-related air pollution in Hong Kong school children | Prof. LAO Xiang Qian |
| 2021.572 | Individual participant data meta-analysis of cohort studies to investigate the health effects of long-term exposure to air pollution: A multi-center study |
Dr. LAO Xiang Qian 勞向前 |
| 2015.175 | Socio-economic inequality trends in cardiovascular risk factors in two Chinese populations with different paces of economic development: analysis of health data from four surveys 2002-2010 |
Prof. LAO Xiang Qian 勞向前 |
| 2015.672 | Health effects of socio-economic status and long-term exposure to ambient PM2.5 in a Chinese population: the MJ Cohort Study |
Dr Lao Xiang Qian 勞向前 |
| 2017.186 | Long-term exposure to ambient PM2.5 pollution and osteoporosis among the elderly in Hong Kong |
Dr. LAO Xiang Qian 勞向前 |
| 2020.410 | Health effects of neighbourhood walkability on Chinese adults: Analysis of an existing longitudinal cohort |
Dr. LAO Xiang Qian 勞向前 |
| 2018.388 | Long-term exposure to ambient air pollution and health in Hong Kong and Taiwan: a cohort study with 0.7 million Chinese |
Dr. LAO Xiangqian 勞向前 |
| 2018.656 | Effect of long-term exposure to multiple air pollutants on respiratory health in Hong Kong primary school children | Dr. LAO Xiangqian |
| 2022.471 | Health Effects of Neighborhood Greenness on Chinese Adults: Analysis of Two Existing Longitudinal Cohorts in Taiwan and Hong Kong |
Dr. LAO Xiangqian 勞向前 |
| 2021.454 | Health effects of long-term exposure to Ozone on Chinese adults: Analysis of an existing longitudinal cohort |
Dr. LAO Xiangqian 勞向前 |
| 2021.233 | Long-term exposure to ambient air pollution and intermediate health outcomes: a cohort study with 55,000 Hong Kong residents |
Dr. LAO Xiangqian 勞向前 |
| 2014.241 | Particulate Matter Air Pollution and Subclinical Atherosclerosis in Hong Kong School Children | Prof. LAO Xiangqian |
| 2014.009 | Health effects of air pollution in Hong Kong primary school environments - a prospective cohort study | Assistant Professor LAO XIANGQIAN |
| 2013.193 | The respiratory health effects of using household cleaning products in Hong Kong school children | Professor Lao Xiangqian |
| 2024.181 | A prospective study to evaluate the diagnostic performance of a wireless optical sensor capsule in detection of upper gastrointestinal bleeding | Prof Lau Louis H.S. |
| 2024.385 | Efficacy of Helmet Therapy for Deformational Plagiocephaly: A Pilot Study | Prof. LAU Adam Yiu Chung |
| 2024.244 | Can Early Nighttime Bracing Prevent High Risk Mild Curve Progressing to Fulltime Bracing in Skeletally Immature Adolescent Idiopathic Scoliosis – A Randomised Controlled Feasibility Study | Prof. LAU Adam Yiu Chung |
| 2024.285 | Follow-up of Adolescent Idiopathic Scoliosis (AIS) Patients after 6-year of Study Enrolment | Prof. LAU Adam Yiu Chung |
| 2023.221 | Artificial Intelligence and machine learning in Adolescent Idiopathic Scoliosis research | Dr. LAU Adam Yiu Chung |
| 2014.061 | Modulation of human mast cell functions by hydrogen sulphide | Prof. LAU Alaster Hang Yung |
| 2015.375 | Comparative study on the effects of morphine on human connective and mucosal mast cells |
Prof. LAU Alaster Hang Yung 劉行榕 |
| 2014.178 | Mast cells activities and osteoporosis - a novel research platform for the study of interaction of herbal and western anti-osteoporosis agents in human | Prof. LAU Alaster Hang Yung |
| 2016.421 | Identification of Genomic Biomarkers in Human Mast Cells |
Prof. LAU Alaster Hang Yung 劉行榕 |
| 2013.155 | Hong Kong Multiple Sclerosis Registry | Dr. LAU Alexander |
| 2013.350 | Long-term, prospective, non-interventional, multinational, parallel-cohort study monitoring safety in patients with MS recently initiated with fingolimod once daily or treated with another approved disease-modifying therapy | Dr. LAU Alexander Yuk Lun |
| 2014.130 | Magnetic Resonance Imaging (MRI) as a biomarker for response to disease modifying therapies for MS patients | Dr. LAU Alexander Yuk Lun |
| 2014.028 | A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO) | Dr. LAU Alexander Yuk Lun |
| 2014.055 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | Dr. LAU Alexander Yuk Lun |
| 2018.450 | Fatigue and Immunomodulatory Responses in Multiple Sclerosis with Integrative Medicine (FIRST) |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2019.679 | A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2019.305 | CUHK Neuroimmunology Biobank Portal (CHERYL) |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2019.595 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2020.556 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2020.456 | A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 1) |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2020.449 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2016.304 | Circadian clock as a novel therapeutic target for multiple sclerosis |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2017.528 | Efficacy and safety of Chinese Medicine Angong Niuhuang Wan for the Treatment of the Stroke: A Randomized, Double-blind,Placebo Controlled Clinical Trial |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2015.709 | An Observational Study to Evaluate Integrative Medicine in Managing Fatigue and Cognitive Deficits Associated with Multiple Sclerosis and Neuromyelitis Optica |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2014.463 | A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | Dr. LAU Alexander Yuk Lun |
| 2013.492 | Prevalence of anti-JC virus antibody in a cohort of Chinese patients with relpasing-remitting multiple sclerosis in Hong Kong | Dr. LAU Alexander Yuk Lun |
| 2017.453 | Outcome prediction of unstructured computed tomography brain imaging of intracerebral hemorrhage |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2016.094 | Quantitative Assessment of Tongue and Pulse Diagnosis for Integrative Chinese and Western Medicine Practice. |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2016.040 | A retrospective analysis of a pilot program “Yan Oi Tong - CUHK Traditional Chinese Medicine Music Therapy Pilot Programme” |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2017.588 | Does surgery reduce mortality in patients with a cerebellar ICH? Observations from an international, multicentre, pooled data set. |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2016.180 | Feasibility of Integrated Large Artery Occlusive Disease Assessment in Acute Ischemic Stroke to Identify Patients with High Risk of Recurrent Stroke and Poor Outcome (FLOW) |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2017.445 | International NMO Genetics Consortium: A Genome-wide Approach for Studying Disease Aetiology |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2016.308 | A retrospective study aiming to explore the disease course, clinical features, electrodiagnostic and laboratory findings of cases with positive Anti-gangliosides antibodies |
Dr. LAU Alexander Yuk Lun 劉玉麟 |
| 2021.714 | A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2021.620 | Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: a pilot add-on, randomised, controlled, pragmatic clinical trial | Dr. LAU Alexander Yuk Lun |
Page 123 of 254.